DIAMEDICA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND NASDAQ LISTING
07. Dezember 2018 07:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Dec. 07, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX‑V:DMA), a clinical stage biopharmaceutical company, announced today the pricing of its...
DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation
12. November 2018 16:45 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 12, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX Venture:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, announced today that it has applied to list...
DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders
06. November 2018 17:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Nov. 06, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, today announced the voting results from its Annual...
DiaMedica Therapeutics and Ahon Pharma, a Fosun Pharma Portfolio Company, Announces Signing of License Agreement for DM199 in China for Acute Ischemic Stroke
27. September 2018 08:52 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS and SHANGHAI, China, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Ahon Pharmaceutical Co Ltd.(Ahon Pharma), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd, (Fosun Pharma, HKG: 02196...
DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer
05. September 2018 08:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Sept. 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) announces the recent appointment of Harry Alcorn Jr. Pharm.D. as...
DiaMedica Issues Stock Option Grant
23. August 2018 19:30 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Aug. 23, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX VENTURE:DMA) (OTCQB:DMCAF), today announces it has issued 600,000 stock options to new employees and...
DiaMedica Announces Positive Results From FDA Meeting on Planned Clinical Trial in Patients with Chronic Kidney Disease
03. Mai 2018 08:30 ET
|
DiaMedica Therapeutics Inc.
DiaMedica has received final minutes from Type B meeting with the US FDADiaMedica preparing to submit an IND to initiate DM199 clinical study in patients with chronic kidney disease in the US ...
DiaMedica Issues Stock Option Grants
17. April 2018 21:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, April 17, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the "Company") (TSX-V:DMA) (OTCQB:DMCAF), today announced the issuance of 2,551,000 stock options to various officers and...
DiaMedica Therapeutics Announces Appointment of Scott Kellen as Chief Financial Officer
05. April 2018 07:15 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, April 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the appointment of Mr. Scott Kellen as Chief Financial...
DiaMedica Therapeutics Announces Final Closing of Private Placement
29. März 2018 18:08 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 29, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company” and “DiaMedica”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the successful completion of the second...